QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RLMD

QT70Relmada Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
6.73
+0.13+1.97%
OverviewShort InterestFilings
RLMDQT70Relmada Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
6.73+1.97%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own6.18%
Shs Outstand104.89M
Perf Week3.22%
Market Cap484.00MForward P/E-EPS next Y-0.96Insider Trans-Shs Float-Perf Month-4.27%
Enterprise Value474.23MPEG-EPS next Q-0.19Inst Own-Short Float-Perf Quarter7.68%
Income-49852196.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y49.56%
Sales-P/B2.61EPS next Y-19.75%ROA-25.02%Short Interest-Perf YTD39.34%
Book/sh-0.09P/C-EPS next 5Y-ROE-71.22%52W High8.00 -15.87%Perf Year855.97%
Cash/sh0.01P/FCF-EPS past 3/5Y-ROIC-27.12%52W Low0.52 1194.23%Perf 3Y-
Dividend Est.-EV/EBITDA-8.05Sales past 3/5Y-Gross Margin0.00%Volatility4.82% 4.17%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM58.87%Oper. Margin0.00%ATR (14)0.43Perf 10Y-
Dividend Ex-Date-Quick Ratio18.26Sales Y/Y TTM-Profit Margin0.00%RSI (14)50.85Recom2.00
Dividend Gr. 3/5Y-Current Ratio18.26EPS Q/Q62.07%SMA201.36%Beta1.58Target Price9.75
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-4.21%Rel Volume3.20Prev Close6.60
Employees17LT Debt/Eq-0.50EarningsAug 06SMA20046.03%Avg Volume1.28MPrice6.73
IPO DateJun 20, 2014Option/ShortYes / YesEPS/Sales Surpr.-22.22% -Net Debt/EBITDA0.17Volume4,104,888Change1.97%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-18-26InitiatedH.CBuy$12
Mar-13-26ReiteratedMizuho Securities$10
Jan-23-26UpgradeLeerink PartnersMarket Perform → Outperform$8.00
Dec-22-25InitiatedJefferiesBuy$8.00 → $9.00
Nov-19-25UpgradeMizuhoNeutral → Outperform
Dec-05-24DowngradeMizuhoOutperform → Neutral
Dec-04-24DowngradeLeerink PartnersOutperform → Market Perform
Jun-05-24DowngradeGoldman SachsNeutral → Sell$2.00
Oct-14-22DowngradeGoldman SachsBuy → Neutral
Oct-14-22DowngradeGuggenheimBuy → Neutral
Latest News
Jun-18-26
Jun-18-2601:38PM
Relmada's Cancer Drug Candidate Sparks Fresh Bullish CallBenzinga
07:45AM
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga
06:06AM
HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
6/30/2019
FY 2017
6/30/2018
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other03849
Research and Development14655
Other Operating Expense5800
Operating Income-59-84-104
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-2-4-5
Net Income Before Taxes-57-80-99
Income Taxes000
Consolidated Net Income-57-80-99
Net Income From Continuing Operations-57-80-99
Net Income-57-80-99
EPS (Recurring)-1.45-2.65-3.28
EPS (Basic, Before Extraordinaries)-1.45-2.65-3.28
EPS (Diluted)-1.45-2.65-3.28
EBITDA-57-805
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding393030
Market Capitalization188——
Operating Lease Expense
———
Insider Trading Volume
$7.19$6.54$5.89$5.24$4.59● Close Price0.00M0.55M1.10M1.65M2.20MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
TRAVERSA SERGIOChief Executive OfficerDec 15 '25Buy4.1227,500113,3001,300,000Dec 16 12:00 AM
Shenouda MagedChief Financial OfficerDec 15 '25Buy4.1211,66548,060800,000Dec 16 12:00 AM
Shenouda MagedChief Financial OfficerNov 05 '25Buy2.20500,0001,100,000788,335Nov 06 12:00 AM
Ence ChuckCAO and COONov 05 '25Buy2.20136,000299,200403,931Nov 06 12:00 AM
TRAVERSA SERGIOChief Executive OfficerNov 05 '25Buy2.20272,500599,5001,272,500Nov 06 12:00 AM
Kelly Paul EdwardChief Operating OfficerNov 05 '25Buy2.2090,000198,000502,295Nov 06 12:00 AM
TRAVERSA SERGIOChief Executive OfficerAug 28 '25Buy0.7455,97641,4221,000,000Aug 28 12:00 AM
TRAVERSA SERGIOChief Executive OfficerAug 27 '25Buy0.67129,45586,735944,024Aug 28 12:00 AM
TRAVERSA SERGIOChief Executive OfficerAug 26 '25Buy0.6280,54549,938814,569Aug 28 12:00 AM
TRAVERSA SERGIOChief Executive OfficerMay 20 '25Buy0.56147,68682,246734,024May 20 12:00 AM
Shenouda MagedChief Financial OfficerMay 20 '25Buy0.5260,00031,422288,335May 20 12:00 AM
Shenouda MagedChief Financial OfficerMay 19 '25Buy0.4990,00043,686228,335May 20 12:00 AM
TRAVERSA SERGIOChief Executive OfficerMay 19 '25Buy0.5030,00014,994586,338May 20 12:00 AM
TRAVERSA SERGIOChief Executive OfficerMay 16 '25Buy0.45172,31477,472556,338May 20 12:00 AM
Shenouda MagedChief Financial OfficerMay 16 '25Buy0.4450,00022,100138,335May 20 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR